AVTR vs. RVTY: Avantor vs. Revvity Stock Comparison
How do Avantor (AVTR) and Revvity (RVTY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Avantor (AVTR) and Revvity (RVTY) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.
| Profile Item | AVTR | RVTY |
|---|---|---|
| Name | Avantor, Inc. | Revvity Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| GICS Sub-Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| Market Capitalization | 10.48 billion USD | 17.31 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | NYSE |
| Listing Date | May 17, 2019 | February 21, 1973 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | AVTR | RVTY |
|---|---|---|
| Total Return (1Y) | 36.41% | 76.75% |
| Total Return (3Y, Annualized) | -5.02% | 24.22% |
| Total Return (5Y, Annualized) | -16.62% | -1.48% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | AVTR | RVTY |
|---|---|---|
| Volatility (1Y, Annualized) | 43.39% | 40.22% |
| Beta (5Y) | 0.94 | 1.07 |
| Max Drawdown (5Y) | -82.42% | -59.01% |
| Avg. Volume (3M) | 8.56M | 1.89M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | AVTR | RVTY |
|---|---|---|
| Sharpe Ratio (1Y) | 0.74 | 1.80 |
| Sortino Ratio (1Y) | 1.17 | 2.90 |
Profitability
ROE (TTM)
Both Avantor (AVTR) at 5.91% and Revvity (RVTY) at 3.45% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.91%
- Max
- 109.18%
- Q3
- 6.23%
- AVTR
- 5.91%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.45%
- Max
- 109.18%
- Q3
- 6.23%
- RVTY
- 3.45%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
For every dollar of sales, both Avantor (AVTR) at 5.08% and Revvity (RVTY) at 8.61% retain more as net profit than most peers, landing in the top net margin quartile of their industries.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.08%
- Max
- 18.05%
- AVTR
- 5.08%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.61%
- Max
- 18.05%
- RVTY
- 8.61%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Revvity (RVTY) at 17.06% operates in the top operating margin quartile, ahead of Avantor (AVTR) at 8.19%, which runs around its industry’s norm.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.19%
- Max
- 83.12%
- Q3
- 14.77%
- AVTR
- 8.19%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
17.06%
- Max
- 83.12%
- RVTY
- 17.06%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | AVTR | RVTY |
|---|---|---|
| ROE (TTM) | 5.91% | 3.45% |
| ROA (TTM) | 2.83% | 2.54% |
| Net Margin (TTM) | 5.08% | 8.61% |
| Operating Margin (TTM) | 8.19% | 17.06% |
| Gross Margin (TTM) | 31.59% | 55.91% |
Growth
Revenue Growth
Revvity (RVTY) at 3.67% is around its peer norm for revenue growth, while Avantor (AVTR) at -3.41% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Revvity (RVTY) at -5.91% is around its peer norm for EPS growth, while Avantor (AVTR) at -175.00% drops into the bottom quartile, signaling weaker earnings momentum.
Growth Metrics
| Metric | AVTR | RVTY |
|---|---|---|
| Revenue Growth (YoY) | -3.41% | 3.67% |
| Revenue Growth (3Y CAGR) | -4.46% | -4.82% |
| EPS Growth (YoY) | -175.00% | -5.91% |
| EPS Growth (3Y CAGR) | -- | -23.26% |
Financial Strength
Current Ratio (MRQ)
Revvity (RVTY) at 2.65 keeps current ratio within its industry’s typical mid-range, while Avantor (AVTR) at 1.89 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for AVTR.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.89
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- AVTR
- 1.89
- Min
- 0.10
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.65
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- RVTY
- 2.65
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both Avantor (AVTR) at 0.63 and Revvity (RVTY) at 0.38 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.63
- Max
- 1.42
- Q3
- 0.65
- AVTR
- 0.63
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.38
- Max
- 1.42
- Q3
- 0.65
- RVTY
- 0.38
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | AVTR | RVTY |
|---|---|---|
| Current Ratio (MRQ) | 1.89 | 2.65 |
| Debt / Equity (MRQ) | 0.63 | 0.38 |
| Net Debt / EBITDA | 3.40 | 2.43 |
Dividends
Dividend Yield (TTM)
Avantor (AVTR) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Revvity (RVTY) reports a yield of 0.19%, ranking against industry peers normally.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- AVTR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.19%
- RVTY
- 0.19%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Avantor (AVTR) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Revvity (RVTY) reports a payout of 13.40%, ranking against industry peers normally.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- AVTR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.40%
- RVTY
- 13.40%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | AVTR | RVTY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.19% |
| Dividend Payout Ratio (TTM) | 0.00% | 13.40% |
Valuation
P/E Ratio (TTM)
Avantor (AVTR) at 30.94 is near its industry’s usual P/E ratio, while Revvity (RVTY) at 68.94 sits in the richer quartile — RVTY needs stronger growth or earnings quality to justify the premium.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.94
- Max
- 85.34
- Q3
- 43.46
- AVTR
- 30.94
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
68.94
- Max
- 85.34
- RVTY
- 68.94
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
Avantor (AVTR) at 1.58 sits in the cheaper P/S ratio quartile while Revvity (RVTY) at 5.88 prices around its industry’s middle — AVTR costs less per dollar of sales, though read it alongside growth and margins.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.58
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- AVTR
- 1.58
- Min
- 0.01
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.88
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- RVTY
- 5.88
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Avantor (AVTR) at 1.80 and Revvity (RVTY) at 2.39 are valued close to their industries’ norm against book — neither stands out from peers.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.80
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- AVTR
- 1.80
- Q1
- 1.69
- Min
- -5.59
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.39
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- RVTY
- 2.39
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | AVTR | RVTY |
|---|---|---|
| P/E Ratio (TTM) | 30.94 | 68.94 |
| P/S Ratio (TTM) | 1.58 | 5.88 |
| P/B Ratio (MRQ) | 1.80 | 2.39 |
| Free Cash Flow Yield (TTM) | 4.21% | 3.62% |